<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"
        xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-news/0.9 http://www.google.com/schemas/sitemap-news/0.9/sitemap-news.xsd http://www.google.com/schemas/sitemap-image/1.1 https://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd">
    <url>
      <loc>https://www.healthdailyfinland.com/article/907473525-orion-pharma-initiates-teadco-phase-1b-2-basket-trial-evaluating-odm-212-in-combination-with-standard-of-care-treatments-in-patients-with-select</loc>
      <news:news>
        <news:publication>
          <news:name>Health Daily Finland</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-23T06:00:00+00:00</news:publication_date>
        <news:title>Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/9e6a027a-eb6c-4e34-993e-b8295e6d598d/small/orionpharma-rgb-press-releases-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.healthdailyfinland.com/article/907473565-orion-pharma-on-aloittanut-teadco-faasi-1b-2-tutkimuksen-odm-212-molekyylill-yhdess-vakiintuneiden-hoitojen-kanssa-potilailla-joilla-on-tiettyj</loc>
      <news:news>
        <news:publication>
          <news:name>Health Daily Finland</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-23T06:00:00+00:00</news:publication_date>
        <news:title>Orion Pharma on aloittanut TEADCO Faasi 1b/2 -tutkimuksen ODM-212-molekyylillä yhdessä vakiintuneiden hoitojen kanssa potilailla, joilla on tiettyjä pitkälle edenneitä kiinteitä kasvaimia</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/9e6a027a-eb6c-4e34-993e-b8295e6d598d/small/</image:loc>
        </image:image>
    </url>
</urlset>
